Brind.
  1. A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
  2. Cybin is operational in Ireland, following its successful product launches and regulatory approvals in various global markets.
  3. Cybin develops treatments for GAD and receives European authorities approval for a Phase 3 trial, which will enroll participants in Australia.

Cybin's CYB004 program is targeting the treatment of GAD.

1 report, 0 independent Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Cybin's CYB004 program is targeting the treatment of GAD.

Who's involved

What this event is mainly about
CybinGAD

Keep exploring

Part of

Cybin develops treatments for GAD and receives European authorities approval for a Phase 3 trial, which will enroll participants in Australia. All 1 developments

Within A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.

The entities involved

Coverage

Newest first; wire copies grouped
  • Unknown outlet